Free Trial

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$482.48 -8.93 (-1.82%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
5
Buy
17

Based on 22 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 5 have given a hold rating, and 17 have given a buy rating for TMO.

Consensus Price Target

$592.24
22.75% Upside
According to the 22 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $592.24. The highest price target for TMO is $686.00, while the lowest price target for TMO is $470.00. The average price target represents a forecasted upside of 22.75% from the current price of $482.48.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMO Analyst Ratings Over Time

TypeCurrent Forecast
9/12/24 to 9/12/25
1 Month Ago
8/13/24 to 8/13/25
3 Months Ago
6/14/24 to 6/14/25
1 Year Ago
9/13/23 to 9/12/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
15 Buy rating(s)
16 Buy rating(s)
14 Buy rating(s)
Hold
5 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$592.24$593.00$605.30$630.41
Forecasted Upside22.75% Upside22.09% Upside50.53% Upside2.65% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificMedical CompaniesS&P 500
Consensus Rating Score
2.77
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside20.55% Upside17,106.86% Upside9.66% Upside
News Sentiment Rating
Very Positive News

See Recent TMO News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/11/2025Barclays
3 of 5 stars
Luke Sergott
Luke Sergott
Not Rated
UpgradeEqual WeightOverweight$490.00 ➝ $550.00+15.30%
9/2/2025Royal Bank Of Canada
3 of 5 stars
Conor McNamara
Conor McNamara
Not Rated
Set TargetOutperform$561.00+15.70%
8/18/2025William Blair
2 of 5 stars
Matt Larew
Not Rated
Initiated CoverageOutperform
7/24/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeStrong-BuyHold
7/24/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$460.00 ➝ $500.00+4.59%
7/24/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$525.00 ➝ $535.00+11.59%
7/24/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$570.00 ➝ $565.00+17.74%
7/24/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuyHold$510.00+6.01%
7/24/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$553.00 ➝ $567.00+21.45%
7/11/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector PerformSector Outperform$590.00+36.75%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$500.00 ➝ $480.00+14.62%
4/29/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$620.00 ➝ $470.00+10.27%
4/24/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$665.00 ➝ $620.00+46.59%
4/23/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetBuy$610.00+41.10%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$650.00 ➝ $570.00+10.42%
1/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$647.00 ➝ $678.00+12.52%
1/10/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$630.00+15.60%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$675.00 ➝ $660.00+26.05%
10/22/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost Target$656.00 ➝ $686.00+16.92%
10/22/2024Bernstein Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetMarket Perform$565.00 ➝ $625.00+6.30%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$680.00+13.74%
10/1/2024Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$680.00+9.93%
9/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$650.00 ➝ $670.00+9.13%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHoldBuy$600.00 ➝ $650.00+14.44%
4/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$600.00 ➝ $610.00+6.54%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$575.00+15.58%
10/26/2023KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOverweightSector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:24 PM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • The current stock price is around $477, which may present a buying opportunity for investors looking for value in the life sciences sector.
  • Thermo Fisher Scientific Inc. has a strong market capitalization of approximately $180 billion, indicating a robust financial position and stability in the market.
  • Recent analyst ratings show a consensus of "Moderate Buy," with many analysts projecting positive growth and a price target significantly higher than the current stock price.
  • The company has a diverse portfolio of life sciences solutions and analytical instruments, which positions it well to capitalize on ongoing advancements in healthcare and research.
  • Thermo Fisher Scientific Inc. has demonstrated resilience with a relatively low debt-to-equity ratio, suggesting a strong balance sheet and lower financial risk.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Recent earnings estimates have been downgraded, indicating potential challenges in meeting growth expectations in the near term.
  • Insider selling activity has been noted, with significant shares sold by executives, which may raise concerns about the company's future performance.
  • The stock has experienced fluctuations, with a one-year high of $623.77 and a low of $385.46, suggesting volatility that could deter risk-averse investors.
  • Analysts have varying price targets, with some lowering their expectations, which could indicate uncertainty about the company's growth trajectory.
  • With a price-to-earnings (P/E) ratio of 27.59, the stock may be considered overvalued compared to industry peers, which could limit upside potential.

TMO Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $592.24, with a high forecast of $686.00 and a low forecast of $470.00.

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There are currently 5 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 22.75% based on their 12-month stock forecasts.

Over the previous 90 days, Thermo Fisher Scientific's stock had 2 upgrades and 2 downgrades by analysts.

Thermo Fisher Scientific has been rated by research analysts at Barclays, Evercore ISI, Hsbc Global Res, HSBC, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Scotiabank, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.

Analysts like Thermo Fisher Scientific less than other "medical" companies. The consensus rating score for Thermo Fisher Scientific is 2.77 while the average consensus rating score for "medical" companies is 2.78. Learn more on how TMO compares to other companies.


This page (NYSE:TMO) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners